Lv41
465 积分 2021-10-18 加入
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
4小时前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
4小时前
已完结
Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement
7天前
已完结
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
8天前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
14天前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
15天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
15天前
已完结
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival
15天前
已完结
Advances in antibody-drug conjugates for endometrial cancer
18天前
已完结
Mirvetuximab soravtansine superior to chemotherapy in platinum-resistant epithelial ovarian cancer
18天前
已完结
皖公网安备34019202002308
